CN111163778A - 一种mor受体激动剂药物组合物 - Google Patents

一种mor受体激动剂药物组合物 Download PDF

Info

Publication number
CN111163778A
CN111163778A CN201980004491.8A CN201980004491A CN111163778A CN 111163778 A CN111163778 A CN 111163778A CN 201980004491 A CN201980004491 A CN 201980004491A CN 111163778 A CN111163778 A CN 111163778A
Authority
CN
China
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
oxaspiro
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980004491.8A
Other languages
English (en)
Other versions
CN111163778B (zh
Inventor
杨晓容
蒋艳霞
陈昊
贺峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Chengdu Suncadia Pharmaceuticals Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Chengdu Suncadia Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Chengdu Suncadia Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN111163778A publication Critical patent/CN111163778A/zh
Application granted granted Critical
Publication of CN111163778B publication Critical patent/CN111163778B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

本披露中涉及一种MOR受体激动剂药物组合物。具体而言，本披露涉及的MOR受体激动剂药物组合物其包含(1S,4S)‑4‑甲氧基‑N‑(2‑((R)‑9‑(吡啶‑2‑基)‑6‑氧杂螺[4.5]癸烷‑9‑基)乙基)‑1,2,3,4‑四氢萘‑1‑胺或其可药用盐，和磷酸盐缓冲液。本披露中之药物组合物在储存数月之后展现了良好的稳定性。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980004491.8A 2018-05-14 2019-05-13 一种mor受体激动剂药物组合物 Active CN111163778B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810455502 2018-05-14
CN2018104555021 2018-05-14
PCT/CN2019/086544 WO2019218953A1 (zh) 2018-05-14 2019-05-13 一种mor受体激动剂药物组合物

Publications (2)

Publication Number Publication Date
CN111163778A true CN111163778A (zh) 2020-05-15
CN111163778B CN111163778B (zh) 2023-01-24

Family

ID=68539514

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980004491.8A Active CN111163778B (zh) 2018-05-14 2019-05-13 一种mor受体激动剂药物组合物

Country Status (3)

Country Link
CN (1) CN111163778B (zh)
TW (1) TW202015678A (zh)
WO (1) WO2019218953A1 (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017063509A1 (zh) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018169A1 (en) * 2007-07-27 2009-02-05 Auspex Pharmaceuticals, Inc. Substituted cyclohexanols
CN103702561B (zh) * 2011-03-23 2017-02-22 特维娜有限公司 阿片样物质受体配体以及使用和制备其的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017063509A1 (zh) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI,XIN ET AL.: "《Discovery of SHR9352: A Highly Potent G Protein-Based u-Opioid Receptor Agonist》", 《ACS OMEGA》 *

Also Published As

Publication number Publication date
CN111163778B (zh) 2023-01-24
TW202015678A (zh) 2020-05-01
WO2019218953A1 (zh) 2019-11-21

Similar Documents

Publication Publication Date Title
US4153689A (en) Stable insulin preparation for nasal administration
KR20030060771A (ko) 국소용 마취제/아편양약물 제제 및 이들의 용도
EP0069600A2 (en) Pharmaceutical compositions
KR20130073948A (ko) 암 치료를 위한 새로운 병용 요법
US20100311774A1 (en) Combination Comprising Paclitaxel for Treating Ovarian Cancer
WO2014204513A1 (en) Atomoxetine solution
RU2398578C2 (ru) Фармацевтическая композиция, содержащая производное таксана, которая предназначена для приготовления инфузионного раствора, способ его приготовления и использование
CN111163778B (zh) 一种mor受体激动剂药物组合物
JP2024501372A (ja) 吸入用医薬組成物
JPS61106509A (ja) 鼻腔用医薬組成物
KR0156929B1 (ko) 안정화된수용성펜타미딘염수용액
US20210046094A1 (en) Compositions and methods for treating pain
JP2000169378A (ja) 咽頭疾患用組成物
CN114569545B (zh) 一种稳定的米托蒽醌制剂
CN114903849A (zh) 一种稳定的液体组合物及其制备方法
CN114096269B (zh) 高浓度胰岛素制剂
CN113069549B (zh) 一种用于改善精子质量的甲基供体组合物
JPH07277965A (ja) 医薬物質および投薬方法
CN116570718A (zh) 一种包含局麻药和磷丙泊酚二钠的药物组合物、其制备方法和用途以及一种联合用药物
CN116456998A (zh) 咖啡因组合物
US20120258937A1 (en) Targeting Estrogen Receptors in the Treatment of Lymphangioleiomyomatosis
CN114376967A (zh) 一种包括羟氯喹的组合物及其制备和应用
WO2023046336A1 (en) Adrenocorticotropic hormone peptide compositions and methods of use
CN117771347A (zh) Glp-1类似物与胰岛素类似物药物组合物制剂及其制备方法和应用
CN114423458A (zh) 含有对二羟硼基苯丙氨酸的注射液剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant